Impact BioMedical Inc

Impact BioMedical’s “going‑concern” audit raises red flags for investors while the firm pushes ahead with a merger‑ambitious Linebacker platform, demanding urgent capital and scrutiny.

Impact BioMedical Inc.’s stock price has plummeted to $0.549, a stark contrast to its 52-week high of $6.17, highlighting the company’s precarious financial standing and the inherent risks in the biotech sector.

Impact Biomedical Inc.’s stock has experienced dramatic fluctuations, with a price drop from $6.17 to $0.37 in just over a month, raising questions about its future prospects and the sustainability of its business model.